Molecular Devices has launched Flipr 3, a more sensitive, higher throughput version of the Flipr fluorometric imaging plate reader system used primarily in high throughput screening
Flipr 3 was on display from 10-13 September at the Society for Biomolecular Screening 7th Annual Conference and Exhibition in Baltimore, USA.
Cell-based screening is a preferred technique in drug discovery because it generates leads with a higher probability of progressing to clinical trials.
All of the major pharmaceutical companies use Molecular Devices' Flipr systems for cell-based screening at all throughput levels - from manual hit-to-lead studies to 24-hour robotic operation.
The new Flipr 3 instrument provides additional capabilities - from higher sensitivity, faster operation and new liquid handling protocols to new detection modes for flash luminescence assays.
"Our customers are expressing heightened interest in cell-based assays," stated Stephen Oldfield, marketing director for drug discovery at Molecular Devices.
"Our Flipr system is the high-throughput method of choice for cell-based assays.
With Flipr 3, the system now enables flash and glow luminescence assay formats while improving throughput and performance with current methods.
"This new instrument platform also extends the user base for our growing family of reagent kits," Oldfield continued.
"Assay kits from Molecular Devices are now being used to screen calcium flux, membrane potential and multidrug resistance on the Flipr system, and for assay development using Molecular Devices' Flexstation benchtop scanning fluorometer and integrated fluid transfer system."
